201 related articles for article (PubMed ID: 8687412)
1. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
[TBL] [Abstract][Full Text] [Related]
2. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
3. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.
Mautz DS; Nelson WL; Shen DD
Drug Metab Dispos; 1995 Apr; 23(4):513-7. PubMed ID: 7600921
[TBL] [Abstract][Full Text] [Related]
4. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.
Crespi CL; Steimel DT; Penman BW; Korzekwa KR; Fernandez-Salguero P; Buters JT; Gelboin HV; Gonzalez FJ; Idle JR; Daly AK
Pharmacogenetics; 1995 Aug; 5(4):234-43. PubMed ID: 8528270
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
6. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
7. Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers.
Uehara S; Ishii S; Uno Y; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 Aug; 45(8):896-899. PubMed ID: 28495902
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes.
Kim M; Shen DD; Eddy AC; Nelson WL; Roskos LK
Drug Metab Dispos; 1993; 21(2):309-17. PubMed ID: 8097702
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
11. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
[TBL] [Abstract][Full Text] [Related]
12. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
[TBL] [Abstract][Full Text] [Related]
13. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
14. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
15. Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6.
Mautz DS; Shen DD; Nelson WL
Pharm Res; 1995 Dec; 12(12):2053-6. PubMed ID: 8786988
[TBL] [Abstract][Full Text] [Related]
16. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
17. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
18. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.
Narimatsu S; Kato R; Horie T; Ono S; Tsutsui M; Yabusaki Y; Ohmori S; Kitada M; Ichioka T; Shimada N; Kato R; Ishikawa T
Chirality; 1999; 11(1):1-9. PubMed ID: 9914647
[TBL] [Abstract][Full Text] [Related]
19. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Smith G; Lightfoot T; Wong MM; Simula AP; Ackland MJ; Sternberg MJ; Lennard MS; Tucker GT
J Biol Chem; 1995 Dec; 270(49):29055-8. PubMed ID: 7493924
[TBL] [Abstract][Full Text] [Related]
20. Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol.
Pepper JM; Lennard MS; Tucker GT; Woods HF
Pharmacogenetics; 1991 Nov; 1(2):119-22. PubMed ID: 1844870
[No Abstract] [Full Text] [Related]
[Next] [New Search]